226 related articles for article (PubMed ID: 36038820)
21. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
22. Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.
Hua H; He W; Chen N; He Y; Wu G; Ye F; Zhou X; Li Y; Ding Y; Zhong W; Teng L; Jiang W; Sheng Q
Front Immunol; 2022; 13():974793. PubMed ID: 36700211
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
24. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
25. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
[TBL] [Abstract][Full Text] [Related]
26. TOX Acts as a Tumor Suppressor by Inhibiting mTOR Signaling in Colorectal Cancer.
Yang M; Huang Q; Li C; Jiang Z; Sun J; Wang Z; Liang R; Li D; Li B; Zhao H
Front Immunol; 2021; 12():647540. PubMed ID: 33897695
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues.
Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496
[TBL] [Abstract][Full Text] [Related]
28. Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer.
Lin A; Zhang H; Hu X; Chen X; Wu G; Luo P; Zhang J
Pharmacol Res; 2020 Sep; 159():105028. PubMed ID: 32569820
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
Link JT; Overman MJ
Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
[TBL] [Abstract][Full Text] [Related]
30. LncRNA profiles from Notch signaling: Implications for clinical management and tumor microenvironment of colorectal cancer.
Dang Q; Liu Z; Liu Y; Wang W; Yuan W; Sun Z; Liu L; Wang C
Front Immunol; 2022; 13():953405. PubMed ID: 35958606
[TBL] [Abstract][Full Text] [Related]
31. Tumor microenvironment-associated gene C3 can predict the prognosis of colorectal adenocarcinoma: a study based on TCGA.
Liu Y; Wang X
Clin Transl Oncol; 2021 Sep; 23(9):1923-1933. PubMed ID: 33765255
[TBL] [Abstract][Full Text] [Related]
32. Mucinous Colorectal Cancer is Associated With Expression of the TIM-3 Immune Checkpoint Independently of Microsatellite Instability (MSI) Status.
O'Connell E; Salvucci M; Reynolds IS; McNamara DA; Burke JP; Prehn JHM
Ann Surg Oncol; 2021 Nov; 28(12):7999-8006. PubMed ID: 33876348
[TBL] [Abstract][Full Text] [Related]
33. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
Shen Y; Guan Y; Hummel JJ; Shyu CR; Mitchem JB
BMC Cancer; 2020 Feb; 20(1):124. PubMed ID: 32059711
[TBL] [Abstract][Full Text] [Related]
34. Emerging glyco-risk prediction model to forecast response to immune checkpoint inhibitors in colorectal cancer.
Qiu P; Chen X; Xiao C; Zhang M; Wang H; Wang C; Li D; Liu J; Chen Y; Liu L; Zhao Q
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6411-6434. PubMed ID: 36757621
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of FAT1 mutations to indicate the immune response in colorectal cancer patients.
Zhu W; Yang L; Gao Y; Zhou Y; Shi Y; Liu K; Yu R; Shao Y; Zhang W; Wu G; He J
Genomics; 2024 Mar; 116(2):110808. PubMed ID: 38364976
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in colorectal cancer.
Agarwal P; Le DT; Boland PM
Adv Cancer Res; 2021; 151():137-196. PubMed ID: 34148613
[TBL] [Abstract][Full Text] [Related]
37. Interferon regulatory factor family influences tumor immunity and prognosis of patients with colorectal cancer.
Chen YJ; Luo SN; Dong L; Liu TT; Shen XZ; Zhang NP; Liang L
J Transl Med; 2021 Sep; 19(1):379. PubMed ID: 34488791
[TBL] [Abstract][Full Text] [Related]
38. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
39. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
[TBL] [Abstract][Full Text] [Related]
40. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
Tan E; Sahin IH
Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
